Transplant News and Research

RSS

UMass Medical School licenses "anti-gal" technology to Agalimmune

The University of Massachusetts Medical School has licensed "anti-gal" technology developed by Professor of Surgery and Medicine Uri Galili, PhD, to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers. Agalimmune is supported by an investment group comprising Loxbridge Research LLP and Animatrix Capital LLP and is based in London and California.

27 Nov 2013

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

Survivors of hematopoietic stem cell transplant benefit from expressive helping

A new study finds that survivors of hematopoietic stem cell transplant, an aggressive treatment for blood cancers, benefited from a two-part peer support process the authors call expressive helping.

27 Nov 2013

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Agalimmune Ltd, a biopharmaceutical company, has been created to develop innovative immunotherapeutics for the treatment of cancer, with a focus on solid tumours.

26 Nov 2013

Cleveland Clinic researchers elected as AAAS Fellows for excellent contributions to science

Cleveland Clinic researchers Richard A. Padgett, Ph.D., and Edward F. Plow, Ph.D., have been named Fellows of the American Association for the Advancement of Science (AAAS). This year's AAAS Fellows will be formally announced in the AAAS News & Notes section of the journal Science on Nov. 29, 2013.

26 Nov 2013

Research: Higher BMI liked with increased risk of hearing loss in women

According to the World Health Organization, 360 million people have disabling hearing loss, a condition that is often considered to be an unavoidable side effect of aging.

26 Nov 2013

FDA grants priority review status to Avedro's riboflavin ophthalmic solution/KXL system

Avedro Inc, a Boston-based ophthalmic medical device and pharmaceutical company announces that it received notification from the U.S. Food and Drug Administration stating that their NDA for riboflavin ophthalmic solution/KXL system has been filed, and has been granted priority review status. The priority review status places the application action date at March 15th, 2014.

25 Nov 2013

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.

23 Nov 2013

New bill offers hope to HIV patients on transplant waiting lists

A bill scheduled to be signed into law today by President Obama reverses the longtime ban on letting HIV-infected people donate their organs for transplantation after death, a move that offers hope to thousands of HIV patients on transplant waiting lists.

22 Nov 2013

Attractants prevent maturing nerve cells from migrating into brain

A vision is to implant nerve precursor cells in the diseased brains of patients with Parkinson's and Huntington's diseases, whereby these cells are to assume the function of the cells that have died off.

21 Nov 2013

People who consume nuts daily are 20% less likely to die

In the largest study of its kind, people who ate a daily handful of nuts were 20 percent less likely to die from any cause over a 30-year period than were those who didn't consume nuts, say scientists from Dana-Farber Cancer Institute, Brigham and Women's Hospital, and the Harvard School of Public Health.

21 Nov 2013

Researchers associate some insomnia symptoms with higher mortality risk in men

Insomnia, the most common sleep disorder, affects up to one-third of the population in the United States. In new findings, researchers from Brigham and Women's Hospital have found that some insomnia symptoms are associated with an increased risk of mortality in men.

20 Nov 2013

Once-daily edoxaban prevents stroke in patients with atrial fibrillation

According to the United States Centers for Disease Control and Prevention, over 800,000 Americans die each year from heart disease and stroke. Stroke is the leading cause of serious long-term disability and death in the US. In addition to lifestyle changes, medications such as anti-blood clotting drugs are helpful in the prevention of stroke.

20 Nov 2013

Heart failure patients receiving LVAD may benefit from injection of powerful cells directly into heart

A multicenter team of researchers within the NIH-funded Cardiothoracic Surgical Trials Network, led by Icahn School of Medicine at Mount Sinai, have found end-stage heart failure patients who receive a surgically implanted left ventricular assist device heart pump may also benefit from a single dose of millions of powerful cells injected directly into their heart during surgery.

19 Nov 2013

Study finds patients treated with varespladib drug more likely to experience cardiovascular events

Patients with acute coronary syndrome who were treated with the experimental drug varespladib were more likely to experience additional cardiovascular events - including sudden death, heart attack and stroke - than those treated with placebo, according to research from the Cleveland Clinic Coordinating Center for Clinical Research (C5Research).

19 Nov 2013

Long-term use of PDE3 inhibitors can lead to increased risk for sudden cardiac death

Drugs known as PDE3 inhibitors save many lives by helping failing hearts do a better job of pumping blood. But those same medications come with a sometimes deadly cost when taken for long periods: an increased risk for sudden cardiac death.

19 Nov 2013

TOPCAT trial results of spironolactone presented at AHA Scientific Sessions

A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial, to be presented at the American Heart Association Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function). However, spironolactone did reduce the major burden faced by these patients-the risk of repeated hospitalizations for heart failure.

19 Nov 2013

Paragonix files second 510(k) with FDA for Sherpa Pak Cardiac Transport System

Paragonix Technologies, Inc. today announced that it has successfully completed filing of a second Pre-Marketing Notification Application (510(k)) with the US Food and Drug Administration (FDA) for its Paragonix Sherpa Pak Cardiac Transport System(CTS).

18 Nov 2013

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.

18 Nov 2013

Experts develop new working formulation for reporting of cardiac antibody-mediated rejection

Antibody-mediated rejection of the transplanted heart is a recognized clinical complication and a major limitation to survival of patients who have undergone heart transplantation. Experts have now developed a new working formulation for the pathologic diagnosis, grading, and reporting of cardiac antibody-mediated rejection.

18 Nov 2013

Transplant News and Research

UMass Medical School licenses "anti-gal" technology to Agalimmune

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Survivors of hematopoietic stem cell transplant benefit from expressive helping

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Cleveland Clinic researchers elected as AAAS Fellows for excellent contributions to science

Research: Higher BMI liked with increased risk of hearing loss in women

FDA grants priority review status to Avedro's riboflavin ophthalmic solution/KXL system

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

New bill offers hope to HIV patients on transplant waiting lists

Attractants prevent maturing nerve cells from migrating into brain

People who consume nuts daily are 20% less likely to die

Researchers associate some insomnia symptoms with higher mortality risk in men

Once-daily edoxaban prevents stroke in patients with atrial fibrillation

Heart failure patients receiving LVAD may benefit from injection of powerful cells directly into heart

Study finds patients treated with varespladib drug more likely to experience cardiovascular events

Long-term use of PDE3 inhibitors can lead to increased risk for sudden cardiac death

TOPCAT trial results of spironolactone presented at AHA Scientific Sessions

Paragonix files second 510(k) with FDA for Sherpa Pak Cardiac Transport System

Kiadis reports successful Phase II enrollment for CR-AIR-007 ATIR blood cancer treatment study

Experts develop new working formulation for reporting of cardiac antibody-mediated rejection

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News